title: Prednicarbate emollient cream 0.1% in pediatric patients with atopic dermatitis.
abstract: Atopic dermatitis, common among infants and children, is an intensely pruritic, chronic, inflammatory dermatosis that is traditionally treated with emollients for dry skin and topical corticosteroids for inflamed areas. A multicenter, 3-week, open-label study evaluated prednicarbate emollient cream 0.1%, a nonhalogenated midpotency corticosteroid, in 55 patients aged 4 months to 12 years who were diagnosed with atopic dermatitis. No suppression of the hypothalamic-pituitary-adrenal (HPA) axis was evidenced by serum cortisol levels obtained before and after intravenous injection of 250 mg of cosyntropin on days 1 and 22, and biochemical tests detected no other systemic effects. Adverse events were few and within the expected range. Prednicarbate resulted in improvements based on global evaluations and sign/symptom scores. In conclusion, this study found prednicarbate emollient cream 0.1% to be safe and effective for the treatment of atopic dermatitis in pediatric patients for up to 3 weeks.
authors.affiliation: University of Pennsylvania, Children's Hospital of Philadelphia, USA.
authors.forename: T
authors.initials: T
authors.lastname: Moshang
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D005938:Glucocorticoids; D006801:Humans; D007223:Infant; D009824:Ointments / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D009824:Ointments; D011239:Prednisolone; C035287:prednicarbate